Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C

Table 3 Treatment tolerability (telaprevir)

	Patients aged < 66	Patients aged ≥ 66	P value
Initial doses (median, range)
PEG-IFN/BW (μg/kg per week)	1.48 (0.98-2.00)	1.49 (1.15-1.87)	0.859
TVR/BW (mg/kg per day)	33.0 (19.2-64.3)	29.2 (7.5-54.2)	0.044
TVR (2250 mg/1500 mg/others), n	55/23/0	11/21/2	< 0.001
RBV/BW (mg/kg per day)	11.4 (6.8-20.0)	11.4 (5.7-28.0)	0.103
Dose reduction, n (%)
PEG-IFN	7 (8.9)	6 (17.6)	0.209
TVR	19 (24.3)	12 (35.3)	0.256
RBV	40 (51.2)	27 (79.4)	0.006
Discontinuation, n (%)
PEG-IFN	13 (16.7)	4 (11.8)	0.580
TVR	12 (15.4)	9 (26.5)	0.192
RBV	12 (15.4)	7 (20.6)	0.585
Adherence, mean ± SD (%)
PEG-IFN	88.2 ± 25.7	90.1 ± 19.8	0.606
TVR	88.8 ± 22.8	83.5 ± 25.5	0.103
RBV	79.3 ± 26.2	62.7 ± 25.3	< 0.001

PEG-IFN: Pegylated interferon; BW: Bodyweight; TVR: Telaprevir; RBV: Ribavirin.